Shares of Spark Therapeutics Inc (NASDAQ:ONCE) have earned an average recommendation of “Hold” from the thirteen research firms that are covering the firm, Marketbeat.com reports. Thirteen investment analysts have rated the stock with a hold recommendation. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $106.00.
A number of analysts recently issued reports on ONCE shares. Zacks Investment Research upgraded Spark Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, December 3rd. ValuEngine downgraded Spark Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, December 3rd.
ONCE traded down $0.99 during trading on Friday, reaching $110.91. The company had a trading volume of 29,833 shares, compared to its average volume of 891,690. The stock has a market cap of $4.29 billion, a P/E ratio of -52.68 and a beta of 2.05. The business has a 50 day simple moving average of $109.91 and a 200-day simple moving average of $103.36. Spark Therapeutics has a 52 week low of $34.53 and a 52 week high of $114.20. The company has a quick ratio of 4.35, a current ratio of 4.67 and a debt-to-equity ratio of 0.35.
Spark Therapeutics Company Profile
Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec) for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells.
Featured Article: What Does a Sell-Side Analyst Rating Mean?
Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.